Foghorn Therapeutics (FHTX) Stock Analysis: AI Score & Alternative Data
Demand signals are heating up for Foghorn Therapeutics
Is Foghorn Therapeutics a buy right now? The alternative data says hold. This FHTX stock analysis is built on the 25+ alternative data signals AltIndex tracks on Foghorn Therapeutics every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 53/100: a Hold. The stock trades at $1.99 with a $124M market cap.
The data leans positive over the past 90 days — revenue up 100.0% YoY to $20M — but the move hasn’t been broad enough to lift FHTX into buy territory yet.
FHTX’s broader alt-data profile also covers headcount (125 employees, according to LinkedIn), and web traffic (4K monthly visits). Every signal links to its own page with full history, the FHTX technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on FHTX is just below.
Foghorn Therapeutics AI Stock Analysis
Foghorn Therapeutics Inc. is a trailblazer in the biotechnology sector, focusing on the development of novel cancer treatments through its unique proprietary gene expression modulation technology. This innovative approach aims to reshape cancer care by targeting the chromatin regulatory system, which is paramount in driving oncogenesis and cancer progression.
Analysis generated September 30, 2026.
Recent Foghorn Therapeutics Stock Alerts
|
Foghorn Therapeutics | October 8 Price is down by -7.7% in the last 24h. |
|
Foghorn Therapeutics | October 7 Price is up by 6.1% in the last 24h. |
|
Foghorn Therapeutics | October 6 Price is down by -7% in the last 24h. |
|
Foghorn Therapeutics | October 2 Price is down by -9.9% in the last 24h. |
Foghorn Therapeutics Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 4K | N/A | |
| Job Posts | 0 | N/A | |
| LinkedIn Employees | 125 | N/A | |
| Reddit Mentions | 0 | N/A | |
| X Mentions | 5 | N/A | |
| Stocktwits Mentions | 25 | 2,400.0% | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 649 | N/A |
About Foghorn Therapeutics (FHTX)
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops drugs that target genetically determined dependencies within the chromatin regulatory system. The company is headquartered in Cambridge, Massachusetts.
| Price | $1.99 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $124M |
| Year Range | $2 – $7 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Foghorn Therapeutics News
View more → |
Foghorn Therapeutics layoffs after Eli Lilly ends cancer dealOctober 2 - Biztoc.com |
See Foghorn Therapeutics’s complete price and AI Score history
Sign up to unlock 1-year and all-time charts for FHTX, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREEFoghorn Therapeutics Earnings & Financial Performance
View all earnings →Foghorn Therapeutics Insider Trading Activity
View all →| Costa Carlos filed to sell 0 shares at $0.0. Sep 23 '24 |
| Costa Carlos filed to sell 0 shares at $0.0. Sep 20 '24 |
| Costa Carlos filed to sell 0 shares at $0.0. Sep 18 '24 |
| Costa Carlos filed to sell 0 shares at $0.0. Sep 17 '24 |
| Costa Carlos filed to sell 0 shares at $0.0. Sep 16 '24 |
Foghorn Therapeutics Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Foghorn Therapeutics
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
Lixte Biotech HldgsLIXT |
$7.21 6.0% | $125M | 43 |
 |
NRx PharmaceuticalsNRXP |
$2.89 0.3% | $126M | 50 |
 |
Tenaya TherapeuticsTNYA |
$0.54 2.0% | $123M | 55 |
 |
TuHURA BiosciencesHURA |
$1.93 2.5% | $126M | 48 |
 |
enGenesENGN |
$1.78 2.0% | $121M | 53 |
Explore Foghorn Therapeutics Data
Frequently Asked Questions: Foghorn Therapeutics (FHTX)
Foghorn Therapeutics has an AltIndex AI Score of 53/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
53/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Foghorn Therapeutics (FHTX) stock is $1.99 with a market cap of $124M.
As of today, Foghorn Therapeutics’s PE (Price to Earnings) ratio is —.
View the latest Foghorn Therapeutics insider transactions to see recent buying and selling activity by company executives and directors.
Check the Foghorn Therapeutics congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The FHTX stock price chart above shows Foghorn Therapeutics’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Foghorn Therapeutics technical analysis for RSI, moving averages, and more.
See the stocks similar to Foghorn Therapeutics section on this page for companies in the same industry ranked by market cap and AI Score.
